Holen Sie sich die Stockscreener-App
6.23
5.95%
0.35
Handel nachbörslich:
6.21
-0.02
-0.32%
Schlusskurs vom Vortag:
$5.88
Offen:
$5.8
24-Stunden-Volumen:
1.39M
Relative Volume:
1.06
Marktkapitalisierung:
$597.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.43M
KGV:
-5.1061
EPS:
-1.2201
Netto-Cashflow:
$-72.75M
1W Leistung:
+8.92%
1M Leistung:
+9.49%
6M Leistung:
-10.87%
1J Leistung:
+200.97%
1-Tages-Spanne:
$5.6296
$6.26
1-Wochen-Bereich:
$5.39
$6.26
52-Wochen-Spanne:
$1.88
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
Firmenname
Zura Bio Ltd
Sektor
Branche
Telefon
858-247-0520
Adresse
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
6.23 | 551.02M | 0 | -75.43M | -72.75M | -1.2201 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Eingeleitet | Wedbush | Outperform |
| 2024-11-04 | Eingeleitet | Leerink Partners | Outperform |
| 2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-05-03 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-10 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2023-08-25 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Guggenheim | Buy |
| 2023-06-14 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-05-24 | Eingeleitet | Raymond James | Strong Buy |
Alle ansehen
Zura Bio Ltd Aktie (ZURA) Neueste Nachrichten
This Zura Bio Insider Increased Their Holding In The Last Year - simplywall.st
Zura Bio (NASDAQ: ZURA) director plans 50,000-share sale after prior trades - Stock Titan
Zura Bio Releases Updated Corporate Presentation in Latest SEC Filing - Kalkine Media
symbol__ Stock Quote Price and Forecast - CNN
Zura Bio (NASDAQ: ZURA) affiliate plans stock sale via option exercise - Stock Titan
Zura Bio updates corporate presentation; HS Phase 2 topline Q4 2026, SSc readout H1 2027, cash runway through 2028 - TradingView
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ZURA (ZURA) insider Someit Sidhu plans 40,000-share sale after option exercise - Stock Titan
Zura Bio Ltd SEC Filing (Aug 13, 2026) - Stock Titan
Wedbush Maintains Zura Bio(ZURA.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Zura Bio Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Guggenheim raises Zura Bio stock price target on new drug indication - Investing.com
Zura Bio Submits Q2 2026 SEC Report Highlighting Financial and Operational Status - Kalkine Media
Zura Bio Q2 Results: EPS Misses Estimate as Losses Widen 23.53% YoY - scanx.trade
Zura Bio Limited Reports Q2 2026 Financial Results and Updates Investor Presentation in 8-K Filing - Kalkine Media
Form 8K Zura Bio Limited For: 11 August By Investing.com - Investing.com Nigeria
Zura Bio Ltd 2Q 2026: Net loss $(26.3)M, EPS $(0.21) — 10-Q Summary - TradingView
Financial update and recent changes drive Zura Bio performance - Traders Union
Zura Bio Completes Enrollment in 247-Participant Hidradenitis Study - Stock Titan
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates - Yahoo Finance
Zura Bio Ltd expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Zura Bio Ltd (ZURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zura Bio (ZURA) Projected to Announce Earnings on Thursday - MarketBeat
1,179,715 Shares in Zura Bio Limited $ZURA Purchased by EcoR1 Capital LLC - MarketBeat
Zura Bio Ltd (ZURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zura Bio Ltd (ZURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zura Bio Ltd (ZURA) Cash Flow - TradingKey
Zura Bio Ltd (ZURA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zura Bio Ltd (ZURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ZURA|Zura Bio Ltd|Price:5.230|Chg%:-0.060 - TradingKey
Zura Bio Ltd (ZURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ZURA|Zura Bio Ltd|Price:5.240|Chg%:-0.140 - TradingKey
TradingKey - TradingKey
Marlyn Teresa Mathew Net Worth (2026) - GuruFocus
William Blair Starts Zura Bio (ZURA) at Outperform - Yahoo Finance
ZURA Initiated Coverage by William Blair -- Rating Set to Outper - GuruFocus
What's Going on With Zura Bio Stock Wednesday?Zura Bio (NASDAQ:ZURA) - Benzinga
Zura Bio navigates growth path amid biotech volatility - Ad-hoc-news.de
William Blair initiates Zura Bio stock with outperform rating By Investing.com - Investing.com Nigeria
William Blair initiates Zura Bio stock with outperform rating - Investing.com
William Blair Initiates Zura Bio(ZURA.US) With Buy Rating - Moomoo
Zura Bio stock. Company profile and listing context. - Ad-hoc-news.de
Wedbush reiterates Outperform on Zura Bio, maintains $15 target - scanx.trade
Zura Bio’s Tibulizumab: First Dual BAFF & IL-17 Bispecific Antibody for Complex Autoimmune Diseases, Advancing in Phase 2 Trials – Minichart - Minichart
Jessica Chen - White & Case LLP
Zura Bio updates corporate presentation; tibulizumab Phase 2 toplines, $225.6M cash (Mar 31, 2026) - TradingView
Zura Bio (NASDAQ: ZURA) furnishes updated corporate presentation for investors - Stock Titan
Guggenheim Maintains Zura Bio(ZURA.US) With Buy Rating, Maintains Target Price $15 - Moomoo
We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely - simplywall.st
Zura Bio completes enrollment in tibulizumab trials By Investing.com - Investing.com South Africa
ZURA Financial Update: Cash Position and Operational Outlook - GuruFocus
Finanzdaten der Zura Bio Ltd-Aktie (ZURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):